Gapping up
In reaction to earnings/guidance:
- NLSN +7.6% (and Experian (EXPGY) announced an expanded strategic initiative to enhance identity data in the United States for digital measurement of the open web), EYE +2.7%, RIDE +1.6%,
M&A news:
- REGI +37.2% ( Chevron in advanced talks to acquire co for approx $61.50/sh), FHN +32.1% (to be acquired in an all-cash transaction valued at $13.4 bln, or $25.00 for each share by TD), .
Other news:
- ABUS +11.3% (and Genevant Sciences (ROIV) filed a patent lawsuit against Moderna (MRNA)
- LHX +3.6% (increases dividend)
- NG +3.1% (reports the final set of assay results from the 2021 drill program)
- OPY +3% (authorizes repurchase of up to 518,000 common shares)
- WRB +2.5% (announces three-for-two stock split)
- NIO +1.3% (announces proposed secondary listing on the stock exchange of Hong Kong)
- IFRX +1.3% (provides update on development plans for vilobelimab in hidradenitis suppurativa)
- EQNR +1.2% (Board of Directors has decided to stop new investments into Russia, and to start the process of exiting Equinor's Russian Joint Ventures)
Analyst comments:
- AXL +5.6% (upgraded to Overweight from Underweight at Morgan Stanley)
- TS +2.1% (upgraded to Overweight from Equal Weight at Barclays)
- PHM +1.4% (upgraded to Buy from Underperform at BofA )